Nanotechnology : United Kingdom nanotechnology stocks

British Biocell International ( BBI )

Benj — Sat, 29 Sep 2007 10:55:54 +0000

Ticker Id

Web url

http://www.bbigold.com/

Contact Email

info@bbigold.com

Short description

Street address

Golden Gate, Ty Glas Avenue

Zip or postal code

CF14 5DX

Telephone

+44 (0) 2920 747232

Fax

+44 (0) 2920 747242

Foundation date

Ceo, president

Number of employees

Long description

Our extensive range of catalogue products is suitable for Light and Electron Microscopy a well as Western blotting. In addition to our wide selection of standard products we can also custom conjugate a provided protein or oligonucloetide.

British Biocell International, part of the AIM listed 'BBI Holdings' group is recognised globally for the production of superior quality gold reagents which are used within lateral flow rapid diagnostic tests for the 'Point of Care' (POC) market.

Since the company developed a unique 'in-house' recipe for the manufacture of superior quality gold nanoparticles in 1986, the company has grown significantly and now offers a growing range of products and services to a global customer base. BBInternational's products and OEM services range from the supply of bulk gold colloid through to high volume manufacture of rapid tests.

The key to BBInternational's success is a proactive focus on rapidly changing market conditions and the ability to exploit key market opportunities.

BBInternational is now the partner of choice for many global blue chip diagnostic companies.

We welcome Shareholders and prospective Shareholders to look through the comprehensive information about British Biocell International and BBI Holdings on the following pages. However, should you have any questions or require further information; please contact us through the link below.

BBI Holdings Plc is incorporated in England and Wales (Reg no.03898291) and its operations are based mainly in the UK.

Additional Commentaries and remarks

Patents

Oxonica

Benj — Fri, 25 Aug 2006 18:00:49 +0000

Ticker Id

Web url

http://www.oxonica.com/

Contact Email

info@oxonica.com

Short description

Street address

7, Begbroke Science Park

Zip or postal code

OX5 1PF

Telephone

+44 (0) 1865 856 700

Fax

+44 (0) 1865 856 701

Foundation date

Ceo, president

Number of employees

Long description

Oxonica operates in the exciting area of nanomaterials. The company is application focused with a portfolio of in-house developed new product opportunities. It also commercialises IPR researched over many years in The University of Oxford.

It employs scientists from the key enabling areas of physics, materials science, chemistry and biochemistry. Its strong commercial team has wide ranging industry experience from electronics and telecommunications through to speciality and performance chemicals.

Oxonica's technology allows it to successfully design, manipulate and engineer certain properties of materials at the nano-scale. It has a portfolio of 22 patents covering materials and applications of commercial significance.

Oxonica's intellectual property derives from a compelling combination of three key technology pillars: solid state physics, colloidal chemistry and coating technology. A large number of potential materials with differing functionalities and surface properties can be generated by Oxonica.

However the company really stands apart because of its expertise in applying the science to short term applications. Oxonica has a strong platform technology - it currently offers commercial products in the fields of fuel catalysis and personal care, and its research and development department is developing a suite of products for diverse sectors including medical diagnostics and security.

The emerging Nanotechnology Industry is broad and diversified and is a sub-sector of the Materials Industry. On the second of July 2003, Science and Innovation Minister Lord Sainsbury announced DTI funding of ВЈ90 million into the nanotechnology sector over the next six years to help industry harness the commercial opportunities offered by this novel technology.

Additional Commentaries and remarks

Patents

SkyePharma Plc (Uk Hq)

Benj — Mon, 21 Aug 2006 14:20:56 +0000

Ticker Id

Web url

http://skyepharma.com/

Contact Email

Short description

Street address

105 Piccadilly

Zip or postal code

W1J 7NJ

Telephone

(44) 207 491 1777

Fax

(44) 207 491 3338

Foundation date

Ceo, president

Number of employees

Long description

SkyePharma has established a number of excellence centres, each specialising in certain drug delivery technologies: SkyePharma AG (oral, topical, inhalation), SkyePharma Sweden (Biosphere injectable), SkyePharma Inc (DepoFoam injectable) and SkyePharma Canada (enhanced solubilizsation).

SkyePharma Research & Development activities for oral, inhalation and topical technologies are conducted in Muttenz near Basel, Switzerland by over 100 scientists, 33 of whom have advanced qualifications in medicine or academic research, with a wide range of expertise, including dry powder formulation, device design, lung biology, aerosol science and chemical and mechanical engineering.

Research & Development and manufacturing for our injectable sustained release DepoFoam technology takes place in San Diego, California, where we have around 56 scientists, 30 of whom hold advanced degrees, including 13 MDs or PhDs. A centre of excellence in the application of enhanced solubilization has been created in Montreal, Canada. There, around 35 experienced scientists implement the most appropriate technology from our extensive portfolio of alternative technologies to improve drug solubility.

Our scientists have a wide range of expertise, including dry powder formulation, device design, lung biology, aerosol science and chemical and mechanical engineering.